businessName
General
Pharmaceutical company whose drugs change the structure of ApoE4, the protein product of a gene associated with a greatly enhanced risk of neurodegenrative disease including Alzheimers, to the structure of ApoE3 or ApoE2 - the benign variants of the same protein. In the scientific literature these drugs have been referred to as 'structure correctors'.
